Advanced Solid Tumor Clinical Trials in Hackensack, New Jersey

11 studies are recruiting for advanced solid tumor in Hackensack, New Jersey right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

    This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    John Theurer Cancer Center Hackensack University Medical Center, Hackensack, New Jersey
    Locations
    28 in total
    Run by
    BeOne Medicines

    See if you can join NCT05981703 on ClinicalTrials.gov

  2. Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

    This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in parti…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Hackensack University Medical Center, Hackensack, New Jersey
    Locations
    34 in total
    Run by
    BeOne Medicines

    See if you can join NCT06598800 on ClinicalTrials.gov

  3. A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

    The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid t…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Hackensack University Medical Center, Hackensack, New Jersey
    Locations
    80 in total
    Run by
    Novartis Pharmaceuticals

    See if you can join NCT04104776 on ClinicalTrials.gov

  4. A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants with selected advanced solid tumors. The study will consist of Phase 1a (Dose Escalation and Safet…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    John Theurer Cancer Center Hackensack University Medical Center, Hackensack, New Jersey
    Locations
    17 in total
    Run by
    BeOne Medicines

    See if you can join NCT07414836 on ClinicalTrials.gov

  5. XTX301 in Patients With Advanced Solid Tumors

    This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Hackensack University Medical Center, Hackensack, New Jersey
    Locations
    12 in total
    Run by
    Xilio Development, Inc.

    See if you can join NCT05684965 on ClinicalTrials.gov

  6. A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

    This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 to 89
    Site
    John Theurer Cancer Center, Hackensack, New Jersey
    Locations
    57 in total
    Run by
    Eikon Therapeutics

    See if you can join NCT06253130 on ClinicalTrials.gov

  7. Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

    This is a single group study of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. The primary purpose of the parts are: * Dose Escalation Part: To evaluate the safety and tolerability …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
    Locations
    28 in total
    Run by
    Daiichi Sankyo

    See if you can join NCT04145622 on ClinicalTrials.gov

  8. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

    The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expa…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    John Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey
    Locations
    19 in total
    Run by
    NiKang Therapeutics, Inc.

    See if you can join NCT06586957 on ClinicalTrials.gov

  9. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Hackensack University Medical Center, Hackensack, New Jersey
    Locations
    21 in total
    Run by
    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

  10. First in Human, Dose Escalation Study of AN4005

    Open-label, multicenter, phase 1 study to investigate the safety, tolerability, and PK of AN4005 in patients with advanced tumors. This study is a first-in-human, dose escalation study with the objective to establish the MTD and/or RP2D of AN4005. Except for Dose Level 0 (50 mg), a traditional "3 +…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Hackensack University Medical Center, Hackensack, New Jersey
    Locations
    7 in total
    Run by
    Adlai Nortye Biopharma Co., Ltd.

    See if you can join NCT04999384 on ClinicalTrials.gov

  11. Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

    This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Hackensack University Medical Center PARTNER, Hackensack, New Jersey
    Locations
    8 in total
    Run by
    Impact Therapeutics, Inc.

    See if you can join NCT05269316 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.